13.80
-0.01(-0.07%)
Currency In USD
| Previous Close | 13.81 |
| Open | 13.61 |
| Day High | 14.03 |
| Day Low | 13.61 |
| 52-Week High | 19.93 |
| 52-Week Low | 9.84 |
| Volume | 7,426 |
| Average Volume | 33,347 |
| Market Cap | 87.72M |
| PE | -2 |
| EPS | -6.9 |
| Moving Average 50 Days | 15.39 |
| Moving Average 200 Days | 15.25 |
| Change | -0.01 |
If you invested $1000 in Assembly Biosciences, Inc. (ASMB) 10 years ago, it would be worth $128.06 as of February 05, 2025 at a share price of $13.8. Whereas If you bought $1000 worth of Assembly Biosciences, Inc. (ASMB) shares 5 years ago, it would be worth $59.19 as of February 05, 2025 at a share price of $13.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
GlobeNewswire Inc.
Dec 26, 2024 1:00 PM GMT
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HB
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
GlobeNewswire Inc.
Dec 19, 2024 1:00 PM GMT
—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity investment raises Gilead’s ownership stake in Assembly Bio to
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial ev